AbbVie: Rinvoq And Skyrizi Will Bridge US Humira Sales Erosion Through 2025
Executive Summary
Continuing its longstanding effort to assure investors about growth past Humira’s US patent expiry in 2023, the pharma outlined label-expansion and market share plans for its two newer immunology drugs.
You may also be interested in...
AbbVie Head-To-Head Data Show Skyrizi Tops IL-17 Competitors In Skin Clearanc
Skyrizi showed better skin-clearance results than Cosentyx or Taltz in a 52-week study of patients who had suboptimal results on the latter two drugs.
AbbVie: Competitor Pricing, Humira Formulary Placement Will Dictate US Biosimilars Impact
Now just months away from the first US Humira biosimilar launch, analysts are asking AbbVie for specifics on expected revenue erosion. CEO Gonzalez said AbbVie aims for 90% formulary coverage in 2023.
AbbVie: Competitor Pricing, Humira Formulary Placement Will Dictate US Biosimilars Impact
Now just months away from the first US Humira biosimilar launch, analysts are asking AbbVie for specifics on expected revenue erosion. CEO Gonzalez said AbbVie aims for 90% formulary coverage in 2023.